Biotec s Soluble Beta-Glucan (SBG ) in clinical applications and its scientific platform

Size: px
Start display at page:

Download "Biotec s Soluble Beta-Glucan (SBG ) in clinical applications and its scientific platform"

Transcription

1 Biotec s Soluble Beta-Glucan (SBG ) in clinical applications and its scientific platform Arctic Biotech Seminar 30 th November 2015 CS Rolf E Engstad

2 Agenda Company Soluble beta-glucan (SBG ) as PAMP SBG as platform for immunotherapeutic applications Healing of stalled wounds Immunotherapy of cancer Summary Biotec Pharmacon ASA 2

3 Biotec Pharmacon Company Established 1990 Listed on SE ticker: biotec About 35 employees Two operating subsidiaries: Biotec Beta-Glucans AS & ArcticZymes AS GMP, IS-13485, and IS 9001 Beta-Glucans Development, production and sales of betaglucans since 1990 Proprietary and patented manufacturing processes Product range from feed grade (M-Glucan ) to pharmaceutical grade (SBG ) GMP approved plant in Tromsø Biotec Pharmacon ASA 3

4 ne source different products Yeast cell walls from yeast extract production (25% BG) M-Glucan Feed ingredient (65% BG) BG Particulate Nutrition (80% BG) BG Cos Cosmetics (90% BG) SBG Soluble Beta-Glucan (Medicinal product) (99% BG) Molecule optimized Biotec Pharmacon ASA 4

5 Innate immunity how is it triggered? The innate immune cells (especially macrophages) has through evolution developed strategies to eliminate pathogenic microbes by recognising conserved structural elements on the surface of each group of pathogens These conserved structural elements on microbes are referred to as PAMPS- «Pathogen Associated Molecular Patterns», and where Betaglucan represents yeast, fungi and a few bacterial species Each PAMP triggers a specific set of reactions in macrophages through selective binding to surface receptors «Training of macrophages by beta-glucan» Saeed et al. Science 2014 Metchnikoff Elia (1887). "Sur la lutte des cellules de l organisme contre l invasion des microbes- n fighting cells of the body against invading microbes. Ann. Inst. Pasteur 1: 32 Biotec Pharmacon ASA 5

6 Biotec SBG trigger innate immune responses Biotec SBG is tailored for optimal binding to white blood cells of the innate immune system, especially the macrophages triggering controlled production of: Production of signal molecules alerting the immune system Production of growth factors supporting cell growth Increased bacterial killing Increased antigen presentation Biotec SBG induces a safe and well regulated response Ideal candidate for many immunotherapeutic applications Biotec Pharmacon ASA 6

7 Uniqueness of SBG The Biotec SBG molecule is tailored to trigger a well regulated innate immune response different from other PAMPs and adjuvants that often have side effects. The SBG having very distinct rheological (gel forming) properties SBG is patent protected by a number of patent families covering production, formulation and application H H H H H H H H H H H H H H n H H H H H H C H 2 H H H H H H Biotec Pharmacon ASA 7 H H H H n H H n H H H H H H C H 2 H H H H

8 Soluble Beta-Glucan Healing of stalled wounds Advanced wound care

9 Regulatory approval of Woulgan Strategic decision to apply for a Medical Device registration of Woulgan Woulgan is approved in the most advanced medical device category in Europe Biotec s SBG is approved as a medicinal substance in Woulgan Woulgan is approved for use in chronic wounds, burns, surgical wounds as well as for more «everyday» wounds Approved main functional claims: moist wound healing properties activation of macrophages Biotec Pharmacon ASA 9

10 Status and strategy for clinical development What we have: Existing Randomised Clinical Trial (double blinded placebo controlled) Surveys in Norway, UK and Germany A comprehensive documentation on mode of action, animal studies etc. What we need: Post Market Clinical Follow-Up ( ongoing) Case study series for local KL support Potential clinical studies to get regulatory approval outside Europe Biotec Pharmacon ASA 10

11 Proliferating cell count (fov) % Contraction SBG in wound care mode of action SBG activates macrophages to produce signal molecules and growth factors resulting in: Wound contraction Wound contraction Cell proliferation Angiogenesis Water Woulgan Biogel «Woulgan Biogel» without SBG 160 Increased healing (ref.: Skjæveland & Engstad 2013) Marginal Intermediate Centre Cell proliferation Marginal Intermediate Centre Biotec Pharmacon ASA 11 Angiogensis Count (fov) Angiogenesis

12 SBG in Diabetic Foot Ulcer clinical data Patients with complete healing (%) SBG Methylcellulose (Placebo control) N= Duration of therapy (weeks) Control Placebo controlled double blinded study of 60 patients Statistical significant after 8 weeks (p=0.03) Treatment schedule: 3 treatments per week Up to 12 weeks treatment Ulcer size 1-34 cm 2 Complete healing (PP): 8 weeks 12 weeks SBG 44% 56% Placebo 17% 31% Biotec Pharmacon ASA 12

13 SBG in wound care clinical data Norwegian survey in 55 patient with mixed wound etiology (most chronic wounds) Woulgan used in practical clinical setting in home care and institutions 72% of clinicians rated the product good to excellent How old is the wound? ver 1 year 37 % Several monts 29 % Up to one week 8 % Several weeks 26 % Wound diagnosis Lacerations Unknown 8 % 6 % Burns 4 % Post-op. Wound 14 % Leg ulcer 28 % Diabetic ulcer 18 % Pressure ulcer 22 % How would you rate Woulgan s effect? Excellent 20 % Don't know 6 % Very good 27 % Poor 10 % Quite good 12 % Good 25 % Biotec Pharmacon ASA 13

14 Agenda Company Soluble beta-glucan (SBG ) as PAMP SBG as platform for immunotherapeutic applications Healing of stalled wounds Immunotherapy of cancer Summary Biotec Pharmacon ASA 14

15 Biotec SBG in cancer therapy -mode of action Enhancing the effector functions of white blood cells SBG shown to induce: Priming/training of phagocytic white blood cells to increased cytokine/ chemokine production Increased recruitment of phagocytic cells to site of mab-labelled cancer cells Increased phagocytic and cytotoxic ability of white blood cells to kill cancer cells Macrophages (monocytes) stimulated with beta-glucan or LPS for 24h and then restimulated 6 days later. Stimulation with beta-glucan results in macrophages in a «Trained Immunity» (A) state giving increased cytokine production (B). Saeed et al 2014, Science, 345: Biotec Pharmacon ASA 15

16 Biotec SBG in cancer therapy animal model Biotec s SBG has been shown to potentiate the effect of immuntherapetic cancer regimes: mab alone Improved anticancer mab effect Improved anticancer vaccine effect mab + SBG SBG enhances the immunepresenting capacity of cells, but more important the effector functions of white blood cells (tumor killing) Biotec s SBG effective when given orally (p.o.) Mice inoculated with human neuroblastoma cancer cells, Treatment with i.v. mab 3F8 with or without p.o. administered SBG. Effect measured as tumor size. (Memorial Sloan Kettering Cancer Center - MSKCC) Biotec Pharmacon ASA 16

17 SBG in immunotherapy of cancer Early phase study performed by Memorial Sloan Kettering Cancer Center in New York Increasing doses of p.o administered SBG combined with i.v. administered monoclonal mab against neuroblastoma in children (45 patients) Combination safe and well tolerated Positive, but transient treatment effects observed Before After Followed up in vaccine trial at MSKCC 123I-MIBG scan of patient treated with one cycle of 3F8+SBG (80mg/kg/day) Biotec Pharmacon ASA 17

18 SBG in immunotherapy of cancer Investigator driven vaccine trial in children with neuroblastoma initiated by MSKCC using their own developed bi-valent vaccine against neuroblastoma antigens (GD2L and GD3L). Biotec s SBG given p.o. to increase tumor killing activity of white blood cells Single arm study Phase I part (safety) of studie (15 patients) finalised in 2013 Combination was safe and positive responses observed Phase II part (efficacy) of study ongoing aiming to recruite 100 patients (115 in total) Kushner et al 2014, Clinical Cancer Research 20: Biotec Pharmacon ASA 18

19 utlook

20 utlook The primary focus of Biotec currently is to secure the full commercial potential of Woulgan Market penetration in Europe Secure the execution of the Post Market Clinical Follow-Up study and local case study series for KL support Develop follow up products for wound healing based the Woulgan technology with SBG The results the ongoing study at Memorial Sloan Kettering Cancer Center will be important references of SBG as an adjuvant for cancer theraphies The Company will assess follow up options for developing SBG within this therapeutic field Biotec Pharmacon ASA 20

Pareto Securities Health Care Seminar Stockholm, 28th August 2015 Svein W. F. Lien CEO

Pareto Securities Health Care Seminar Stockholm, 28th August 2015 Svein W. F. Lien CEO Pareto Securities Health Care Seminar Stockholm, 28th August 2015 Svein W. F. Lien CEO Agenda Highlights Q2 financials Beta-Glucans advanced wound care Enzymes molecular testing Outlook 2 Highlights Q2

More information

Presentation Nordnet 23 rd January Svein W. F. Lien CEO

Presentation Nordnet 23 rd January Svein W. F. Lien CEO Presentation Nordnet 23 rd January 2014 Svein W. F. Lien CEO Agenda Highlights Q3 and 9M financials Beta-glucans advanced wound care Enzymes molecular testing Summary and Outlook 2 Highlights by Q3 Beta-glucans

More information

Immunity for Life TM

Immunity for Life TM Immunity for Life TM DnB NR Markets Health Care Summit 2006 Prof. Dr. Jan Raa, Chief Scientific fficer 19 September 2006 A biomedical company Pharmaceutical development program + Cash generating businesses

More information

Inflammation and Cancer

Inflammation and Cancer Inflammation and Cancer A H PD C C B P Why Care About The Role Inflammation In Cancer? In a state of perpetual activation, immune mediators (cytokines, chemokines, free radicals) may cause tissue damage

More information

Q4 Presentation. Oslo, 11 th February 2016. Svein W. F. Lien CEO

Q4 Presentation. Oslo, 11 th February 2016. Svein W. F. Lien CEO Q4 Presentation Oslo, 11 th February 2016 Svein W. F. Lien CEO Agenda Highlights Q4 Financials BetaGlucans Advanced wound care Enzymes Molecular testing Outlook Biotec Pharmacon ASA 2 Highlights Q4 Quarterly

More information

Presentation Third quarter 2006

Presentation Third quarter 2006 Immunity for Life TM Presentation Third quarter 2006 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2006 Highlights - operations Phase II diabetic ulcers trial; supports proof-ofconcept Encouraging effects

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

We want to keep prostate cancer from coming back. We re looking for 711 men who want to help.

We want to keep prostate cancer from coming back. We re looking for 711 men who want to help. We want to keep prostate cancer from coming back. We re looking for 711 men who want to help. IMPORTANT INFORMATION FOR PROSTATE CANCER PATIENTS The odds are already in your favor. If you have been diagnosed

More information

Chapter 17A: Adaptive Immunity Part I

Chapter 17A: Adaptive Immunity Part I Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

Ph.D. in Molecular Medicine

Ph.D. in Molecular Medicine Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to

More information

Immunity. Humans have three types of immunity innate, adaptive, and passive: Innate Immunity

Immunity. Humans have three types of immunity innate, adaptive, and passive: Innate Immunity Immunity Humans have three types of immunity innate, adaptive, and passive: Innate Immunity Everyone is born with innate (or natural) immunity, a type of general protection. Many of the germs that affect

More information

DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER

DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER Drug Development Office 100 DRUG DEVELOPMENT AND OPERATIONAL STAFF NEW AGENTS IN CLINICAL

More information

Name (print) Name (signature) Period. (Total 30 points)

Name (print) Name (signature) Period. (Total 30 points) AP Biology Worksheet Chapter 43 The Immune System Lambdin April 4, 2011 Due Date: Thurs. April 7, 2011 You may use the following: Text Notes Power point Internet One other person in class "On my honor,

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

Microbiology AN INTRODUCTION EIGHTH EDITION

Microbiology AN INTRODUCTION EIGHTH EDITION TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein

More information

CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES

CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES An understanding of the distinct families of molecules present on different cells of the immune system provides the tools for distinguishing

More information

Clinical trials preclinical requirements. Clinical trials - legislation

Clinical trials preclinical requirements. Clinical trials - legislation Clinical trials preclinical requirements Mikael Andersson, PhD Senior Expert Medical Products Agency, Sweden Tallinn 9/10 2009 Clinical trials - legislation Directive 2001/20/EC Clinical trial directive

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

and Antigen Presentation

and Antigen Presentation 1 Innate Immunity and Antigen Presentation Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Innate immunity Receptors and mechanisms Roles in disease Antigen

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

2) Macrophages function to engulf and present antigen to other immune cells.

2) Macrophages function to engulf and present antigen to other immune cells. Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components

More information

Introduction. Skin. The Immune System. Chapter 51

Introduction. Skin. The Immune System. Chapter 51 The Immune System Chapter 51 Introduction Vertebrates have three levels of defenses -1. The Integumentary System -Skin and mucous membranes provide first line of defense -2. Nonspecific (innate) Immune

More information

B Cells and Antibodies

B Cells and Antibodies B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production

More information

Immunology. Lecture- 3

Immunology. Lecture- 3 Immunology Lecture- 3 Complement System complement system is a part of the immune system that helps or complements the ability of antibodies and phagocytic cells to destroy and clear pathogens and viruses.

More information

11/20/2011. Outline. Immune System Function. Terminology. Two Types of Immune Defense. Innate Immunity = Non Specific

11/20/2011. Outline. Immune System Function. Terminology. Two Types of Immune Defense. Innate Immunity = Non Specific Chapter 43 Immune System Outline I. Nonspecific Defenses A. Barrier B. Protective proteins C. Phagocytes D. Natural killer cells E. Inflammatory reaction II. Specific Defenses A. B cells Antibody mediated

More information

ENDORSED BY THE GOVERNANCE COMMITTEE

ENDORSED BY THE GOVERNANCE COMMITTEE Guideline for the Preparation or Manipulation of Monoclonal Antibodies (MABs) and related compounds such as Fusion Proteins, used in the Treatment of Cancer Date Approved by Network Governance July 2012

More information

ANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1

ANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1 AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL

More information

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based

More information

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables Abstract Abbreviations List of figures CONTENT I-VI VII-VIII IX-XII List of tables XIII Chapter 1 Review of Literature 1. Vaccination against intracellular pathogens 1-34 1.1 Role of different immune responses

More information

Immunotherapy Concept Turned Reality

Immunotherapy Concept Turned Reality Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a

More information

Technological platforms

Technological platforms Advitech Advitech is a life sciences & technology company Its mission is to discover and commercialize proprietary and evidence-based natural health products Focus on milk, whey and bovine colostrum R&D,

More information

PharmaceuticalDevelopment

PharmaceuticalDevelopment PharmaceuticalDevelopment Activities & Timelines Agenda Factors driving development Types of product Timelines for development Factors affecting length of development Regulation of Pharma environment Cost

More information

Gordon Pedersen Ph.D. Abstract

Gordon Pedersen Ph.D. Abstract A Clinical Review of the Treatment of Diabetic Ulcers, Pressure Ulcers and Venous Stasis Ulcers in Human Subjects Using Silver Sol Gel While Residing in a Geriatric Health Care Facility By Gordon Pedersen

More information

Antigens have specific regions where antibodies bind to them Antigens are usually molecules on the surface of viruses or foreign cells Antigenic

Antigens have specific regions where antibodies bind to them Antigens are usually molecules on the surface of viruses or foreign cells Antigenic Bio 100 Guide 22 Antigens have specific regions where antibodies bind to them Antigens are usually molecules on the surface of viruses or foreign cells Antigenic determinants are the specific regions on

More information

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

More information

Hapten - a small molecule that is antigenic but not (by itself) immunogenic.

Hapten - a small molecule that is antigenic but not (by itself) immunogenic. Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

IMMUNOLOGY STRUCTURE AND FUNCTION OF IMMUNE SYSTEM

IMMUNOLOGY STRUCTURE AND FUNCTION OF IMMUNE SYSTEM 59 IMMUNOLOGY STRUCTURE AND FUNCTION OF IMMUNE SYSTEM 59.1 INTRODUCTION The immune system is engaged in a constant surveillance of the body for pathogens or tumors. Whether disease develops depends on

More information

Microbiology 532 Immunology Examination KEY October 30, 2003

Microbiology 532 Immunology Examination KEY October 30, 2003 KEY October 30, 2003 All questions have equal point value. You may keep the test questions. Multiple Choice (choose the best answer) 1. Receptors associated with innate immunity recognize microbes by detecting:

More information

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works. November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also

More information

DNA Vaccine: A Defense against Bioterrorism?

DNA Vaccine: A Defense against Bioterrorism? DNA Vaccine: A Defense against Bioterrorism? Gema Puspa Sari Budiman Bela Virology and Cancer Pathobiology Research Center for Health Service (VCPRC) FKUI-RSCM Introduction DNA Vaccine Using genetically

More information

Chapter 22: The Lymphatic System and Immunity

Chapter 22: The Lymphatic System and Immunity Chapter 22: The Lymphatic System and Immunity Introduction Immune system the body s defenses against pathogens that produce disease 2 types of immunity Nonspecific immune mechanisms (Innate immunity) Provide

More information

The Adaptive Immune System

The Adaptive Immune System Chapter 17 Functional Anatomy of Prokaryotic and Eukaryotic Cells Lectures prepared by Christine L. Case The Adaptive Immune System Learning Objectives 17-1 Differentiate innate from adaptive immunity.

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 2. Modification of the gut microbiota to promote human health 1. Bacteriocins are: b. Bacterially produced heat-stable antimicrobial peptides 2. Prebiotics, probiotics,

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Chugai Pharmaceutical Co., Ltd. Oncology Area, Scientific Group 2, Breast Cancer Group Takehiro Yamaguchi, Herceptin Product Manager

Chugai Pharmaceutical Co., Ltd. Oncology Area, Scientific Group 2, Breast Cancer Group Takehiro Yamaguchi, Herceptin Product Manager Anti-malignant Tumor Agent with Anti-HER2 Humanized Monoclonal Antibody: Biologics, Designated drug, Prescription drug HERCEPTIN Injection 60 HERCEPTIN Injection 150 Trastuzumab (genetical recombination)

More information

Innate immunity: Definition and Importance. Updated: July 2015

Innate immunity: Definition and Importance. Updated: July 2015 Innate immunity: Definition and Importance Updated: July 2015 1 Contents INNATE IMMUNITY... 3 DEFINITION AND IMPORTANCE... 3 Overview of innate immunity in animals... 3 The innate immune system acts early

More information

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry

More information

Immune cells from healthy people pulverise cancer

Immune cells from healthy people pulverise cancer Published on ScienceNordic (http://sciencenordic.com) Home > Printer-friendly PDF > Printer-friendly PDF Immune cells from healthy people pulverise cancer Health[1] Health[1]Cancer research [2]immune system

More information

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

More information

Drug treatments for kidney cancer

Drug treatments for kidney cancer James Whale Fund for Kidney Cancer Drug treatments for kidney cancer Before your doctors can discuss treatment options with you they need to know how far your cancer has progressed. Staging is used to

More information

Monoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C

Monoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C Monoclonal Antibody Therapy: Innovations in Cancer Treatment James Choi ENGL 202C Treating Cancer with Monoclonal Antibody Therapy Researchers and scientists have been working for decades to find a cure

More information

The Body s Defenses CHAPTER 24

The Body s Defenses CHAPTER 24 CHAPTER 24 The Body s Defenses PowerPoint Lectures for Essential Biology, Third Edition Neil Campbell, Jane Reece, and Eric Simon Essential Biology with Physiology, Second Edition Neil Campbell, Jane Reece,

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 3, September 17, 2015 Engineering the Immune System to Recognize Myeloma Cells Speakers Moderator: David Avigan, MD Harvard

More information

ANATOMY OF THE IMMUNE SYSTEM THE IMMUNE SYSTEM. ANATOMY OF THE IMMUNE SYSTEM Thymus glandular organ near the heart where T cells learn their jobs

ANATOMY OF THE IMMUNE SYSTEM THE IMMUNE SYSTEM. ANATOMY OF THE IMMUNE SYSTEM Thymus glandular organ near the heart where T cells learn their jobs THE IMMUNE SYSTEM 1 ANATOMY OF THE IMMUNE SYSTEM 2 We all get sick sometimes...but then we get better. What happens when we get sick? Why do we get better? The immune system is localized in several parts

More information

Chapter 43: The Immune System

Chapter 43: The Immune System Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2

More information

Immune System. Daryl Beatty Brazosport College Anatomy & Physiology II

Immune System. Daryl Beatty Brazosport College Anatomy & Physiology II Immune System Daryl Beatty Brazosport College Anatomy & Physiology II 21 The Immune System: Innate and Adaptive Body Defenses Which of the following best describes the immune system? a. the set of organs

More information

The Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense

The Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense The Immune System 2 Types of Defense Mechanisms Immune System the system that fights infection by producing cells to inactivate foreign substances to avoid infection and disease. Immunity the body s ability

More information

Healing Music Proven by Medical Research

Healing Music Proven by Medical Research Healing Music Proven by Medical Research Medical, Mathematical and Scientific Proof Illustrates Efficacy of Sacred Healing Music October 2015 New York City, NY At the Memorial Sloan Kettering Cancer Center

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Amphibian Immunology. Vertebrate Immunology. Lymphoid Organs 3/4/14

Amphibian Immunology. Vertebrate Immunology. Lymphoid Organs 3/4/14 Amphibian Immunology Heather Williamson University of Tennessee Department of Microbiology March 4, 2014 Vertebrate Immunology Lymphoid Organs 1 3/4/14 Immunity First Line of Defense 2 Innate Immunity:

More information

Supplemental Material CBE Life Sciences Education. Su et al.

Supplemental Material CBE Life Sciences Education. Su et al. Supplemental Material CBE Life Sciences Education Su et al. APPENDIX Human Body's Immune System Test This test consists of 31 questions, with only 1 answer to be selected for each question. Please select

More information

Acting Out the Immune Response An Activity for the Middle School Life Science Classroom

Acting Out the Immune Response An Activity for the Middle School Life Science Classroom Acting Out the Immune Response An Activity for the Middle School Life Science Classroom by Lindsay E. Porter Pollard Middle School 200 Harris Avenue Needham, MA 02492 lindsay_porter@needham.k12.ma.us Table

More information

2. Surface barriers include the and of the respiratory, gastrointestinal

2. Surface barriers include the and of the respiratory, gastrointestinal The Immune System: Innate Host Defenses 1. Name the two major categories of innate (nonspecific) defenses: 2. Surface barriers include the and of the respiratory, gastrointestinal and genitourinary tracts.

More information

Chapter 43: The Immune System

Chapter 43: The Immune System Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2

More information

Making the switch to a safer CAR-T cell therapy

Making the switch to a safer CAR-T cell therapy Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction

More information

Recognise phagocytes and lymphocytes under the light microscope;

Recognise phagocytes and lymphocytes under the light microscope; Immunity The immune system Vaccination Learning Objective Recognise phagocytes and lymphocytes under the light microscope; The following micrographs show as to how different types of phagocytes and lymphocytes

More information

immunotherapy a guide for the patient

immunotherapy a guide for the patient immunotherapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2 immunotherapy... 5 Monoclonal Antibodies... 6 Vaccines... 7 Adoptive T-Cell Transfer... 8 Oncolytic Viruses...

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Osteosarcoma: treatment beyond surgery

Osteosarcoma: treatment beyond surgery Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma

More information

PlantForm Corporation

PlantForm Corporation PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

EMA and Progressive Multifocal Leukoencephalopathy.

EMA and Progressive Multifocal Leukoencephalopathy. EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of

More information

Biological Therapies for Cancer: Questions and Answers. Key Points

Biological Therapies for Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Biological Therapies for

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

Corporate Presentation June 2, 2015

Corporate Presentation June 2, 2015 Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these

More information

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010 RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines

More information

Biotechnology in Medicine and Agriculture

Biotechnology in Medicine and Agriculture Biotechnology in Medicine and Agriculture Bởi: OpenStaxCollege It is easy to see how biotechnology can be used for medicinal purposes. Knowledge of the genetic makeup of our species, the genetic basis

More information

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Medical Therapies Limited EGM Presentation

Medical Therapies Limited EGM Presentation Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for

More information

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India.

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION TO CLINICAL TRIAL Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION The safety and toxicity data generated from

More information

Immune system. Nonspecific response: inflammation. Inflammation : the beginning. Nonspecific immunity vs. Adaptive immunity

Immune system. Nonspecific response: inflammation. Inflammation : the beginning. Nonspecific immunity vs. Adaptive immunity Immune system Body must resist disease in order to function Defends against pathogens, identifies and destroys abnormal cells. The primary pathogens are bacteria and viruses. Nonspecific immunity vs. Adaptive

More information

Pathogens and the immune system

Pathogens and the immune system Review of lecture 7 Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu BRC 511 / 530-lab Lecture 8 BIOE 301-Bioengineering and World Health Science Science is the human activity of

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

Metastatic Breast Cancer...

Metastatic Breast Cancer... DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a

More information

Pathogens and the immune system

Pathogens and the immune system Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu BRC 511 / 530-lab Lecture 8 BIOE 301-Bioengineering and World Health Review of lecture 7 Science Science is the human activity of

More information

CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS

CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS See APPENDIX (1) THE PRECIPITIN CURVE; (2) LABELING OF ANTIBODIES The defining characteristic of HUMORAL immune responses (which distinguishes them from CELL-MEDIATED

More information

Understanding How Existing and Emerging MS Therapies Work

Understanding How Existing and Emerging MS Therapies Work Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of

More information

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;

More information

GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS -ii- GUIDELINES ON THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND

More information

Innate Host Defenses Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com).

Innate Host Defenses Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Innate Host Defenses Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Page 1: Introduction Surface barriers (the skin, mucous membranes,

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

Adaptive Immunity in Organ Transplantation

Adaptive Immunity in Organ Transplantation Adaptive Immunity in Organ Transplantation Rainer Krebs Transplantation Laboratory Cardiopulmonary Research Group 12-02-2014 Adaptive vs innate immunity INNATE immunity: first line of defense quick reaction,

More information

Biological Therapies for Cancer

Biological Therapies for Cancer Biological Therapies for Cancer Key Points Biological therapies use the body's immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Biological therapies

More information

Additional file 1. Progress of phase II clinical trials of Panagen

Additional file 1. Progress of phase II clinical trials of Panagen Additional file 1. Progress of phase II clinical trials of Panagen Documentation Phase II clinical trial of preparation Panagen was performed in compliance with the following documentation: Approval of

More information

Chapter 18: Applications of Immunology

Chapter 18: Applications of Immunology Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing

More information

DanDrit Biotech OTCQB:DDRT

DanDrit Biotech OTCQB:DDRT DanDrit Biotech OTCQB:DDRT Developing the World s First Colorectal Cancer Vaccine Investor Dagen - Copenhagen. March 2015 Disclaimer This presentation may contain forward-looking statements, including

More information